About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed

Sample Content 

LOGIN


Sign up to stay informed--receive email notifications for this journal

Cancer Biotherapy and Radiopharmaceuticals

Editors: Donald J. Buchsbaum, PhD and Robert K. Oldham, MD

ISSN: 1084-9785 • 10 Issues Annually • Online ISSN: 1557-8852

Current Volume: 29

Latest Impact Factor* is 1.381

*2013 Journal Citation Reports® published by Thomson Reuters, 2014

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    Instructions for Authors

    All manuscripts should be submitted via our online system: http://mc.manuscriptcentral.com/Cancerbiotherapy

     

    Be sure these instructions are followed exactly.
     

    Abstracts
    ABSTRACT should be capitalized and centered on the page and have one space below. The text of the abstract is single spaced and should be limited to 200 words. This should appear on a separate page.

    Key words
    Please provide a short list of key words to follow the Abstract.  You will also be asked to enter keywords during online submission.

    Tables and Figures
    Each table should be prepared in a separate file. Tables should be cited in the text (see Table 1). Tables should be submitted in Microsoft Word.
     

    Each figure should be prepared in a separate file with the figure number visible. Each figure should be cited in text (Fig. 1). Legends should be on a separate page from the figures.

     

    Please follow these guidelines for submitting figures: 

    • Do NOT embed art files into a Word or PDF document.
    • Line illustrations should be submitted at 1200 dpi.
    • Halftones and color should be submitted at a minimum of 300 dpi.
    • Save as either TIFF or EPS files.
    • Color art must be saved as CYMK – not RGB.
    • Black and White art must be submitted as grayscale not RGB.
    • Do NOT submit PowerPoint, PDF, Bitmap or Excel files.

    Please name your artwork files with the submitting author's name i.e. SmithFig1.tif, SmithTable2.tif etc. Label figures and tables inside the files in addition to naming the file with the figure or table number. (ie: When figures or table files are opened, the figure or table number should appear inside the file.)  Authors who do not follow these guidelines may have their submission returned to them without being reviewed.

    You will be given directions on how to correct any files which do not pass.


    ADDITIONAL INFORMATION ABOUT ART FILES

     

    Converting Word or Excel files: Perhaps the best and easiest way to convert Word or Excel files into a format which is suitable for print is to scan them using the guidelines below : 

    •  All files should be scanned at 100% size.
    • 300 dpi
    • Final color mode: cmyk
    • save file as: .tif or .eps

    If you need directions on how to convert a Power Point slide to acceptable format go to http://www.liebertpub.com/MEDIA/pdf/ppconvert.pdf

    Footnotes

    Footnotes should be typed single spaced at the bottom of the appropriate page and separated from the text by a 3-inch line starting from the left margin with one space above and below it. Footnotes should be used only when essential.

    Acknowledgments

    Collaborations, sources of research funds, and other acknowledgments must be listed in a separate section at the end of the text ahead of the REFERENCES section.

    AUTHOR DISCLOSURE

    All authors are expected to disclose any institutional or commercial affiliations that might pose a conflict of interest regarding the publication of a manuscript. Institutional affiliations, as indicated on the title page, should include all corporate affiliations and any funding sources that support the work. Other types of affiliation, including consultantships, honoraria, stock ownership, equity interests, arrangements regarding patents, or other vested interests should be disclosed in the Acknowledgments section.

    References

    Cite references within the text by a superscripted Arabic number as in the following example: [. . .as described previously. 1,4 ]. List references by number (1, 2, etc.) in the order in which they appear in the text. Type single spaced, although separated from each other by one line of space. Use Chemical Abstracts format for references. For journal citations: (1) surname of author(s) and initials; (2) title of article; (3) journal; (4) volume number; (5) first page of citation; and (6) year in parentheses. For book citations: (1) surname of author(s) and initials; (2) title of book; (3) editor of book (if applicable); (4) edition of book (if applicable); (5) publisher; (6) city of publication; (7) year of publication (not in parentheses); and (8) page reference (if applicable). For book and journal references, if there are more than four authors, list only the first three, followed by et al. For patents: (1) country of original registration; (2) patent number; and (3) month, day, and year of issuance. When data from an unpublished source are given, supply complete information (e.g., researcher’s name and location). If work is in press, give journal in which it is to be published or publisher.

    IMPORTANT

    Please upload individual files of all manuscript material—do NOT upload a single PDF file containing all text, figure, and table files of your paper. Once all individual files are uploaded onto Manuscript Central, the system will automatically create a single PDF proof for you and the peer-review process.

    Permissions

    Written permission to use copyrighted material must be obtained from the publisher (not the author or editor). The publication from which the figure, table, or text is taken must be listed in REFERENCES. Finally, the first footnote of a reprinted table, or the last sentence of the legend of a reprinted figure, should read “reprinted by permission from Ref. (00),” using appropriate reference number. All permissions must be listed.

    Correspondence

    Be sure to provide the complete name and address to which correspondence should be directed.

    Disclosures

    Funding sources for research must be disclosed for all manuscripts accepted for publication.

    Reprints

    Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.

    Publisher

    The Journal is published 10 times per year by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215. Telephone: (914) 740-2100; fax: (914) 740-2101; e-mail: info@liebertpub.com; online: www.liebertpub.com.
     

     

  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy


    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.

     

    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 

     

     

     

Recommended Publications

You may be interested in the following publications:

    Journal of Interferon
    & Cytokine Research

    Journal of Interferon
    & Cytokine Research

    Presents the latest findings and reviews of research covering IFNs and cytokines, their relevance to chronic and acute disease, studies involving cytokine biology, mechanisms of IFN action, and their role in virus infection.

    Human Gene Therapy

    Human Gene Therapy

    The definitive rapid-publication journal covering all aspects of gene therapy through original investigations into the transfer and expression of genes in mammals, with in-depth coverage of DNA, RNA, and cell therapies.

    ASSAY and Drug Development Technologies

    ASSAY and Drug Development Technologies

    This authoritative, rapidly peer-reviewed journal features original articles, application-oriented technology reviews, and reports in methodology and technology application.

    Stem Cells and Development

    Stem Cells and Development

    Globally recognized as the trusted source for critical, even controversial coverage of emerging hypotheses and novel findings on stem cells of all tissue types and their potential therapeutic applications.

Browse All Publications »